176 related articles for article (PubMed ID: 37945918)
1. Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma.
Cui H; Lian J; Xu B; Yu Z; Xiang H; Shi J; Gao Y; Han T
Sci Rep; 2023 Nov; 13(1):19512. PubMed ID: 37945918
[TBL] [Abstract][Full Text] [Related]
2. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
3. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
4. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
Lei H; Xiang T; Zhu H; Hu X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
[TBL] [Abstract][Full Text] [Related]
5. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
8. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy.
Wu H; Liu TT; Feng YM; Xie XY; Su XN; Qi JN; Zhu Q; Qin CY
J Dig Dis; 2020 Nov; 21(11):650-663. PubMed ID: 32959529
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
10. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
11. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Yan J; Zhou C; Guo K; Li Q; Wang Z
J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
[TBL] [Abstract][Full Text] [Related]
12. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
[TBL] [Abstract][Full Text] [Related]
13. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
Front Immunol; 2022; 13():856186. PubMed ID: 35479067
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
Cao J; Wu L; Lei X; Shi K; Shi L; Shi Y
Bioengineered; 2021 Dec; 12(1):673-681. PubMed ID: 33622186
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma.
Chen R; Chen Y; Huang W; Zhao Y; Luo W; Lin J; Wang Z; Yang J
Aging (Albany NY); 2021 Jul; 13(13):17607-17628. PubMed ID: 34237706
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a m7G-related lncRNA signature for predicting the prognosis and therapy response in hepatocellular carcinoma.
Peng YL; Dong YF; Guo LL; Li MY; Liao H; Li RS
PLoS One; 2023; 18(8):e0289552. PubMed ID: 37535570
[TBL] [Abstract][Full Text] [Related]
18. Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma.
Ma Y; Luo T; Dong D; Wu X; Wang Y
Gene; 2018 Jul; 663():148-156. PubMed ID: 29684484
[TBL] [Abstract][Full Text] [Related]
19. Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes.
Shi Q; Yuan X; Xue C; Gu X; Li L
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239939
[TBL] [Abstract][Full Text] [Related]
20. A five lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Sun Y; Zhang F; Wang L; Song X; Jing J; Zhang F; Yu S; Liu H
Mol Med Rep; 2019 Jun; 19(6):5237-5250. PubMed ID: 31059056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
